<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is a ubiquitous human gamma-herpesvirus that infects about 95% of the adult population </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of <z:e sem="disease" ids="C0948192" disease_type="Disease or Syndrome" abbrv="">primary infections</z:e> occurs in early childhood and is generally subclinical; it can cause <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> (IM), which is usually a self-limiting <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of EBV occasionally results in severe, often lethal diseases, which include fatal IM, <z:mpath ids='MPATH_654'>hemophagocytic syndrome</z:mpath>, polyclonal <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, and malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>These severe EBV-related illnesses occur secondary to some primary <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> diseases showing inefficient immune reaction to EBV </plain></SENT>
<SENT sid="4" pm="."><plain>One example is <z:hpo ids='HP_0001417'>X-linked</z:hpo> <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> (XLP), which is caused by mutations in the SLAM-associated protein (SAP) gene </plain></SENT>
<SENT sid="5" pm="."><plain>The major clinical manifestations of XLP are fulminant IM, malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0002961'>dysgammaglobulinemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001915'>Aplastic anemia</z:hpo>, virus-associated <z:mpath ids='MPATH_654'>hemophagocytic syndrome</z:mpath>, and <z:hpo ids='HP_0002633'>vasculitis</z:hpo> have also been reported in XLP </plain></SENT>
<SENT sid="7" pm="."><plain>We have developed a flow cytometric method using the anti-SAP monoclonal antibody to search for XLP </plain></SENT>
<SENT sid="8" pm="."><plain>This clinically useful assay has successfully been used to identify XLP patients in Japan </plain></SENT>
<SENT sid="9" pm="."><plain>In this review, clinical and mutational characteristics of XLP in Japan are mainly described </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, it is shown that the similar situations to XLP can occur in other primary <z:hpo ids='HP_0002721'>immunodeficiencies</z:hpo> involving T-cell killing function, such as <z:e sem="disease" ids="C1328840" disease_type="Disease or Syndrome" abbrv="ALPS">autoimmune lymphoproliferative syndrome</z:e> caused by Fas gene mutations or <z:e sem="disease" ids="C0272199" disease_type="Neoplastic Process" abbrv="FHL|FEL|HPLH1|FHLH|HPLH|HLH1">familial hemophagocytic lymphohistiocytosis</z:e> caused by perforin gene mutations </plain></SENT>
<SENT sid="11" pm="."><plain>Finally, the EBV-related terrible disease condition, namely <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e>, which is common in Asian areas but its genetic background remains to be elucidated, will be touched on </plain></SENT>
</text></document>